MGI Tech Co., Ltd. recently held an investor conference, providing a detailed interpretation of its plan to acquire two entities for 366 million yuan. Through the integration of spatiotemporal omics and nanopore sequencing technologies, the company is set to become the world's only life science enterprise with a complete product matrix encompassing "full-length sequencing + spatial omics." Management focused on explaining the commercialization achievements of the two assets and their future application potential during the meeting.
Cyclone SEQ series products have demonstrated significant market expansion success since their launch in September 2024, with the customer base widely covering universities, research institutes, CDC centers, hospitals, and sequencing service providers. The products have also successfully entered overseas markets such as Asia-Pacific and Latin America, indicating steady progress in global deployment. The application layout for nanopore sequencing continues to deepen, including the establishment of a long-read 100,000-person cohort alliance aimed at promoting the large-scale application of the technology in cohort projects. To further broaden application scenarios, the core product G100-E is scheduled for medical device clinical registration application submission in the second half of 2025, with registration expected to be completed in 2026. Post-registration, efforts will intensify to deploy the product in high-value clinical diagnostic scenarios, fully unleashing its clinical application value.
Simultaneously, tailored solutions have been launched in various fields including public health, animal diseases, food testing, and environmental monitoring, continuously expanding the application boundaries of nanopore sequencing technology. The anticipated revenue growth for the nanopore sequencing business post-merger is supported by multiple core factors. Firstly, there is dual support from market space and synergistic effects; according to Data Bridge Market Research, the global long-read sequencing market has a CAGR of approximately 22%. The combination of nanopore sequencing technology with the company's existing DNBSEQ high-throughput sequencing technology forms a complete SEQALL solution with complementary long and short reads, better meeting diverse research and clinical needs and significantly enhancing the company's market penetration. Secondly, channel integration and cost optimization efforts are underway; the nanopore products will continue to be promoted leveraging the company's mature global sales network, while economies of scale and supply chain integration will reduce unit costs, further improving market competitiveness.
Finally, application scenarios will be continuously expanded. The nanopore technology holds significant advantages in specific scenarios such as high-GC content genome analysis, complex structural variation analysis, fragment repeats, and rapid pathogen detection. Future efforts will focus on developing these areas to create new revenue growth points. Additionally, multi-omics solution bundling will be promoted, combining nanopore technology with single-cell sequencing, automated library preparation, and spatiotemporal omics to enhance customer stickiness. The specific implementation path will emphasize deepening cross-selling to existing customers by providing one-stop bundled solutions; formulating specialized promotion plans for advantageous application scenarios; and optimizing pricing strategies to attract a broader user base, thereby driving revenue growth comprehensively.
The core of spatiotemporal omics technology lies in analyzing the complete mechanisms of life development from both temporal and spatial dimensions, including processes from a fertilized egg to a complete organism, or from a seed to a towering tree. Concurrently, the technology can be applied to disease research like cancer, providing support for developing precise clinical treatment plans by analyzing individual differences in drug therapy efficacy for cancer patients. As a cutting-edge technology in life sciences with a relatively short history, the spatiotemporal omics business has already accumulated over 200 customers, approximately half of which are industrial clients, with the remainder being academic and research institutions. From a business promotion perspective, the high customer repurchase rate strongly confirms the practical value of the technology, effectively aiding customers in advancing their research and clinical translation studies. Looking ahead, the company anticipates this technology may replicate the development path of high-throughput sequencing, achieving widespread adoption and playing a core role in clinical applications.
Currently, the spatiotemporal omics business has implemented differentiated strategies across global regions. In China, it leverages the rapid expansion of ecosystem partners to deepen local service capabilities; in the Americas, it targets top academic institutions to establish high-end technology benchmarks; in Asia-Pacific, it reaches various potential customers through diverse channels; and in Europe, it has formed a multi-faceted, balanced cooperation network covering both research and clinical fields. The business has achieved the critical leap from zero to one in each region, laying a solid foundation for subsequent scaled growth.
In future market deployment, the company will employ a dual-track approach to further expand customer coverage: In the domestic market, it will continue to strengthen ecosystem synergies and focus on攻坚 clinical scenarios, translating technological advantages into clear clinical value and consolidating its leading market share. In overseas markets, it will establish global influence through benchmark clients, create technology demonstration effects, implement精细化 "one country, one policy" operations, and achieve comprehensive deployment from product export to technology ecosystem and brand standards, systematically widening the market moat.
The core competitive advantage of spatiotemporal omics technology is its breakthrough in addressing the industry pain point of balancing "high resolution" and "large field of view." The technology boasts three globally leading characteristics that form its differentiated advantage: it has achieved an ultra-high resolution of 500 nanometers, covering 400 pixels relative to a 10-micrometer diameter cell, enabling precise segmentation and analysis of gene expression in single cells,彻底 solving the issue some competitors face with fine observation at the single-cell level. This provides key support for精细 research like tumor microenvironment studies, cell-cell interaction analysis, and bacterium-host interaction studies. Furthermore, it possesses a unique global capability for large-field-of-view analysis at 13x13 cm, suitable for research on centimeter-scale organs in mice and humans, allowing whole-tissue studies without segmentation and effectively avoiding key information loss common in traditional segmented studies, offering a superior solution for analyzing inter-tissue relationships in research and clinical fields. Additionally, the technical team has successfully broken through the barrier of detecting embedded tissue samples after years of effort, achieving globally leading performance in the number of genes detected from paraffin-embedded sample spatial detection. With vast archives of long-term preserved paraffin pathology samples in hospitals worldwide awaiting transformation from traditional morphological studies to multi-omics research, this technological breakthrough meets this demand precisely and has been deployed in countries including China and the US, laying a foundation for clinical translation research and future routine testing.
Leveraging its outstanding technical advantages, the spatiotemporal omics technology has gained high recognition from the global industry. As of December 31, 2025, it has assisted global scientists in publishing over 400 high-level research papers and serves more than 1,000 research institutions across over 20 countries. Looking forward, the business will focus on two core directions to build growth engines: In the research field, it will continuously broaden application boundaries, deeply exploring application value in diverse areas such as neuroscience, brain-computer interfaces, embryonic development, agricultural breeding, and forensic testing to unleash the technology's scenario potential. In the clinical field, as a core development track, the company has collaborated with global pharmaceutical companies and hospital experts to conduct digital spatiotemporal pathology analysis and initiated the Third Global Spatiotemporal Omics and Spatiotemporal Pathology Alliance in Chongqing late last year. Through industry-academia-research collaboration, it aims to accelerate the deployment and industrial application of this globally leading technology, building core competitiveness in clinical translation to create long-term value for the company.
Comments